{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:44:47Z","timestamp":1777538687203,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T00:00:00Z","timestamp":1381881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Roche Products Pty Limited (Australia)"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      Rituximab is one of nine biologic agents approved for the treatment of rheumatoid arthritis (\n                      <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\n                      ) in Australia. The primary study objective was to analyze the factors that lead to the therapeutic decision to use rituximab in\n                      <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cross\u2010sectional, retrospective chart review was conducted to identify patients who were treated with rituximab and to evaluate their response to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Factors influencing the prescription of rituximab were identified. The most commonly reported reason for prescribing rituximab was the presence of comorbidities and the presence of seropositive disease. Median rituximab treatment duration was 32.5\u00a0months and mean number of treatment cycles was 4.1. Disease activity scores showed significant improvement from baseline to most recent visit. Rituximab treatment was well\u2010tolerated in this group of\n                      <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\n                      patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Rituximab was effective in a refractory group of\n                      <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\n                      patients and appears to be safe in a population with a high prevalence of comorbidities, including malignancy and recurrent infections\/bronchiectasis. This study may assist rheumatologists in selecting appropriately targeted therapy in\n                      <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1756-185x.12164","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T10:02:53Z","timestamp":1381917773000},"page":"755-761","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in\n                    <scp>A<\/scp>\n                    ustralian rheumatology practice"],"prefix":"10.1111","volume":"17","author":[{"given":"Dave","family":"Nicholls","sequence":"first","affiliation":[{"name":"Coast Joint Care Maroochydore Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Zochling","sequence":"additional","affiliation":[{"name":"Menzies Research Institute Tasmania Hobart Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Boers","sequence":"additional","affiliation":[{"name":"Maryvale Private Hospital Morwell Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Champion","sequence":"additional","affiliation":[{"name":"Ashford Specialists Centre Ashford South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mathers","sequence":"additional","affiliation":[{"name":"Georgetown Arthritis Georgetown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Riordan","sequence":"additional","affiliation":[{"name":"Illawarra Rheumatology Wollongong New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital Camperdown and Sydney University Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Scott","sequence":"additional","affiliation":[{"name":"Roche Products Pty Limited (Australia) Dee Why New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedley","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Barwon Rheumatology Service Geelong Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140"},{"key":"e_1_2_7_3_1","unstructured":"Roche Products Pty Limited.Rituximab (Mabthera) Product Information. Australia 2013."},{"key":"e_1_2_7_4_1","unstructured":"Bristol\u2010Myers Squibb Australia Pty Ltd.Abatacept (Orencia) Product Information. Australia 2012."},{"key":"e_1_2_7_5_1","unstructured":"AbbVie Pty Ltd.Adalimumab (Humira) Product Information. Australia 2012."},{"key":"e_1_2_7_6_1","unstructured":"Invida Australia Pty Limited.Anakinra (Kineret) Product Information. Australia 2013."},{"key":"e_1_2_7_7_1","unstructured":"UCB Pharma.Certolizumab (Cimzia) Product Information. Australia 2012."},{"key":"e_1_2_7_8_1","unstructured":"Pfizer Australia Pty Limited.Etanercept (Enbrel) Product Information. Australia 2013."},{"key":"e_1_2_7_9_1","unstructured":"Janssen Cilag Pty Ltd.Golimumab (Simponi) Product Information. Australia 2012."},{"key":"e_1_2_7_10_1","unstructured":"Janssen Cilag Pty Ltd.Infliximab (Remicade) Product Information. Australia 2013."},{"key":"e_1_2_7_11_1","unstructured":"Roche Products Pty Limited.Tocilizumab (ACTEMRA) Product Information. Australia 2011."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"e_1_2_7_13_1","first-page":"622","article-title":"Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis","volume":"33","author":"Ostor AJ","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-006-0491-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10535"},{"key":"e_1_2_7_18_1","first-page":"1590","article-title":"Etanercept\u2010related extensive pulmonary nodulosis in a patient with rheumatoid arthritis","volume":"34","author":"van Ede A","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_19_1","first-page":"752","article-title":"Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti\u2010TNF\u2010alpha therapy","volume":"29","author":"Stefano R","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20311"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.008"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.03.025"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21260"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22536"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker289"},{"issue":"3","key":"e_1_2_7_28_1","first-page":"71","article-title":"Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease","volume":"70","author":"Dass S","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201117"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087023"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12164","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:50:42Z","timestamp":1695462642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,16]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/1756-185X.12164"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12164","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718325318.793492812","asserted-by":"object"}]},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,16]]},"assertion":[{"value":"2013-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}